Dr Dan Zandberg reviews the latest understanding in the use of checkpoint inhibition in SCCHN through an examination of 3 cases.
This activity is intended for oncologists, surgeons, and pathologists.
The goal of this activity is to increase understanding of the use of checkpoint inhibition in advanced squamous cell carcinoma of the head and neck (SCCHN) as well as ongoing research into its use earlier in the disease setting.
- Have increased knowledge regarding the evidence-based management of patients with SCCHN
- Have increased knowledge regarding the role of cancer immunotherapy clinical trials
- Have greater competence related to selecting the most appropriate cancer immunotherapy regimen for patients with SCCHN
- Have greater competence related to managing immune-related adverse effects
Approximate Time to Complete: 1 hour
Credit Available: May 9, 2019 - May 9, 2020
Developed through a partnership between SITC and Medscape.
Additional Resources for Clinicans from SITC:
"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)" (Published July 15, 2019)